Leukoreduction and ultraviolet treatment reduce both the magnitude and the duration of the HLA antibody response

BackgroundBoth leukoreduction and ultraviolet (UV) light treatment of blood products have been shown to reduce the incidence of HLA antibody development in recipients, but the impact of these treatments on the magnitude and persistence of the antibody response is less clear. Study Design and MethodsLongitudinal samples from 319 subjects taken from four different study cohorts were evaluated for HLA antibodies to determine the effects of leukoreduction and UV treatment on HLA antibody generation and persistence. ResultsSubjects receiving leukoreduced or UV-treated blood products were less likely to generate Class I HLA antibodies, and those receiving leukoreduced blood were also less likely to generate Class II HLA antibodies. Among those receiving nonleukoreduced blood, 55% developed Class I HLA antibodies and 51% developed ClassII HLA antibodies compared with 28% (ClassI) and 15% (ClassII) for those receiving leukoreduced blood and 36% (ClassI) and 54% (ClassII) for those receiving UV-treated blood. Among alloimmunized subjects, leukoreduction resulted in a significant twofold reduction in the magnitude of ClassI HLA antibodies, and UV treatment resulted in a significant threefold reduction in the magnitude of ClassII HLA antibodies. Both treatments resulted in shorter persistence of ClassI HLA antibodies. ConclusionsThese data demonstrate that leukoreduction and UV treatment of blood products results not only in a reduction in the incidence of HLA antibody production, but also in lower and more transient HLA antibody levels among sensitized transfusion recipients.